摘要
目的观察替吉奥一线治疗老年进展期胃癌的近期有效性及安全性。方法 56例老年进展期胃癌患者随机分为两组：治疗组28例口服替吉奥胶囊40 mg/m^2,Bid,d1-28,q5w;对照组28例口服卡培他滨片1250 mg/m^2,Bid,d1-14,q3w;化疗3个周期后评价近期疗效及不良反应。结果 56例均可评价;治疗组和对照组的近期有效率（RR）分别为46.4%和42.9%,两组比较差异无显著性（P〉0.05）,但治疗组的不良反应及严重反应发生率均明显低于对照组（P〈0.01）。结论替吉奥治疗老年进展期胃癌的疗效较好,不良反应轻,值得临床进一步研究应用。
Objective To examine the short-term efficacy and safety of S-1 in the treatment of old patients with advanced gastric carcinoma.Methods Fifty-six old patients with advanced gastric carcinoma were randomly divided into two groups.S-1（40 mg/m^2）was taken by mouth in the experimental group,bid,d1-28,q5w;Capecitabine（1250 mg/m^2）was taken by mouth in the control group,bid,d1-14,q3w.Short-term efficacy and adverse reactions were evaluated after three treatment cycles.Results The response rates（RR）of the experimental group and the control group were 46.4% and 42.9%,respectively.The difference between two groups was not statistically significant（P0.05）.However,compared with the control group,the occurrence rate of adverse reactions and serious reactions were apparently lower in the experimental group（P0.01）.Conclusions The regimen of S-1 showed good efficacy in the treatment of old patients with advanced gastric carcinoma,and the adverse reactions was relatively mild and tolerable.These results indicate that further clinical study is worthy.
出处
《中国肿瘤临床与康复》
2011年第1期61-63,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
胃肿瘤/化学治疗
老年
替吉奥
卡培他滨
Gastric neoplasms/chemotherapy
Old patients
S-1
Capecitabine
